Theses›Robotics & physical AI›Surgical robotics

Surgical robotics

Surgical robotics is the most commercially mature, profitable robotics segment (~$8-14bn 2025, ~13-14% CAGR).

  • Bear
  • Shut
  • $38B by 2035

The callSurgery outruns surgeons and autonomy works on the bench, but Intuitive holds the operating room; the consensus has this right and the value is with listed companies.

D1D2R1R2R3C1foragainst D1D2R1R2R3C1foragainst
Fig. 1The balance. Drivers and catalysts against restraints, each block sized by its weight; catalysts hang dashed because they have not happened yet, sized by their odds. It tips toward the restraints.
  1. D1Demand for surgery outruns the surgeons, and every da Vinci needs a trained surgeon driving it for the whole case, so the incumbent's model scales with surgeons.
  2. D2Autonomy works on the bench: in July 2025 the SRT-H system removed gallbladders on pig tissue 8 times out of 8 with no human stepping in.
  3. R1Intuitive's installed base and recurring instruments lock hospitals in, and da Vinci 5 brought haptics and placed 303 systems in one quarter.
  4. R2Regulation and surgeon training run the incumbent's way; the training cycle is the moat.
  5. R3Challengers need FDA de novo clearance plus a $1.5M-class system, and CMR took $200M in one round and still ended up a Stryker option.
  6. C1A regulator clears an autonomous surgical sub-task such as suturing or dissection, which breaks the surgeon-scaling model.2028
Rests onthe beliefs underneath
Supported by · confidence
What would prove itdated tests, open and resolved
202720282029today12345predictionswatch 202720282029today12345predictionswatch
Fig. 2Each ring is a dated test: dashed while open, struck through when overdue, ticked or crossed once resolved.
  1. 1Through end-2027 no post-2022 surgical-robotics entrant has reached both regulatory clearance (FDA/CE) and more than 25 commercial system placements against Intuitive's installed base.Dec 2027 · open
  2. 2A post-2022 entrant clears and places more than 25 systems.Dec 2027 · open
  3. 3Through 2028 Intuitive Surgical retains soft-tissue robotic-surgery dominance (majority installed base) despite Hugo / Versius / Ottava clearances, and tip-force haptics becomes table-stakes.Dec 2028 · open
  4. 4Intuitive keeps a majority of the soft-tissue base and haptics becomes standard on every new platform.Dec 2028 · open
  5. 5A regulator clears an autonomous sub-task, or a force-sensing component company holds its own value at a major maker.Dec 2028 · open
Expressionslisted, private, technologies
  • ISRGIntuitive Surgical, Inc.
    • full
  • MDTMedtronic plc
    • full
  • SYKStryker Corporation
    • full
  • JNJJohnson & Johnson MedTech
    • not screened
     Sells the Monarch bronchoscopy robot (from Auris) and the Ottava soft-tissue robot (FDA De Novo Jul 2026) to hospitals; division of J&J.
  • ZBHZimmer Biomet
    • not screened
     Sells the ROSA robotic system for knee (and hip) replacement to hospitals, paired with its implants.
  • SN.LSmith+Nephew
    • not screened
     Sells the CORI handheld robotic system for knee and hip replacement to hospitals.
  • 2252.HKMicroPort MedBot
    • not screened
     Makes the Toumai laparoscopic robot, SkyWalker orthopaedic robot and R-One vascular robot, sold mainly to Chinese hospitals.
Private · 6 private companies.

Medical Microinstruments (MMI) · Noah Medical · Moon Surgical · Cornerstone Robotics · Ronovo Surgical · ForSight Robotics

1 more private company tracked, not shown

Technologies
Who has already bet on itprivate rounds, from public sources

$1.1B raised by 6 companies, $741M of it in the last three years. Wave under way: Large rounds in the last three years; the category is funded and getting crowded.

Backed by a top-tier venture firm: Medical Microinstruments (MMI), Noah Medical, Moon Surgical. Backed by a strategic investor: Moon Surgical.